JP2022512937A - Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 - Google Patents

Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 Download PDF

Info

Publication number
JP2022512937A
JP2022512937A JP2021524317A JP2021524317A JP2022512937A JP 2022512937 A JP2022512937 A JP 2022512937A JP 2021524317 A JP2021524317 A JP 2021524317A JP 2021524317 A JP2021524317 A JP 2021524317A JP 2022512937 A JP2022512937 A JP 2022512937A
Authority
JP
Japan
Prior art keywords
polypeptide
clazakizumab
months
transplantation
solid organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524317A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020097566A5 (https=
JP2022512937A5 (https=
Inventor
スタンレー・シー・ジョーダン
アシュリー・ヴォー
ノリコ・アマーマン
ジュア・チョイ
Original Assignee
セダーズ－シナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セダーズ－シナイ メディカル センター filed Critical セダーズ－シナイ メディカル センター
Publication of JP2022512937A publication Critical patent/JP2022512937A/ja
Publication of JPWO2020097566A5 publication Critical patent/JPWO2020097566A5/ja
Publication of JP2022512937A5 publication Critical patent/JP2022512937A5/ja
Priority to JP2024135834A priority Critical patent/JP2024161505A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021524317A 2018-11-08 2019-11-08 Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 Pending JP2022512937A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135834A JP2024161505A (ja) 2018-11-08 2024-08-16 Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862757676P 2018-11-08 2018-11-08
US62/757,676 2018-11-08
US201962855988P 2019-06-01 2019-06-01
US62/855,988 2019-06-01
PCT/US2019/060622 WO2020097566A1 (en) 2018-11-08 2019-11-08 Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135834A Division JP2024161505A (ja) 2018-11-08 2024-08-16 Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用

Publications (3)

Publication Number Publication Date
JP2022512937A true JP2022512937A (ja) 2022-02-07
JPWO2020097566A5 JPWO2020097566A5 (https=) 2022-11-07
JP2022512937A5 JP2022512937A5 (https=) 2022-11-07

Family

ID=70612280

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524317A Pending JP2022512937A (ja) 2018-11-08 2019-11-08 Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用
JP2024135834A Pending JP2024161505A (ja) 2018-11-08 2024-08-16 Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135834A Pending JP2024161505A (ja) 2018-11-08 2024-08-16 Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用

Country Status (9)

Country Link
US (1) US20210395358A1 (https=)
EP (1) EP3877412A4 (https=)
JP (2) JP2022512937A (https=)
KR (1) KR20210089719A (https=)
CN (1) CN112969711B (https=)
AU (1) AU2019374905A1 (https=)
BR (1) BR112021007633A2 (https=)
CA (1) CA3117386A1 (https=)
WO (1) WO2020097566A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20220073605A1 (en) * 2018-12-20 2022-03-10 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
US20220288202A1 (en) * 2019-09-04 2022-09-15 Cedars-Sinai Medical Center Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients
KR20230009096A (ko) 2021-07-08 2023-01-17 주식회사 엘지에너지솔루션 리튬 이차전지용 양극 슬러리 조성물, 양극 및 이를 포함하는 리튬 이차전지

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US20110111437A1 (en) * 2009-10-08 2011-05-12 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers For Prognosis of Pulmonary Diseases
WO2011066374A2 (en) * 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20170174760A1 (en) * 2015-07-24 2017-06-22 Cedars-Sinai Medical Center Method for treating antibody-mediated rejection post-transplantation
US20200123238A1 (en) * 2017-04-19 2020-04-23 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI, J. ET AL., AM J TRANSPLANT, vol. 17, JPN6023039805, 2017, pages 2381 - 2389, ISSN: 0005304821 *
NCT03380377, CLAZAKIZUMAB FOR CHRONIC AND ACTIVE ANTIBODY MEDIATED REJECTION POST-KIDNEY TRANSPLANT,, JPN6023039804, 26 February 2018 (2018-02-26), ISSN: 0005304820 *

Also Published As

Publication number Publication date
US20210395358A1 (en) 2021-12-23
JP2024161505A (ja) 2024-11-19
AU2019374905A1 (en) 2021-06-10
CN112969711B (zh) 2024-12-17
EP3877412A4 (en) 2022-08-10
WO2020097566A1 (en) 2020-05-14
CA3117386A1 (en) 2020-05-14
BR112021007633A2 (pt) 2021-10-13
EP3877412A1 (en) 2021-09-15
CN112969711A (zh) 2021-06-15
KR20210089719A (ko) 2021-07-16

Similar Documents

Publication Publication Date Title
JP2024161505A (ja) Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用
US20250263480A1 (en) Clazakizumab in the Treatment of Chronic Antibody-Mediated Rejection of Organ Transplant
JP2019506412A (ja) 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体
JP6506172B2 (ja) 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
US20230348611A1 (en) Obinutuzumab treatment of a dlbcl patient subgroup
CN114007700A (zh) 抗FcRn抗体在治疗天疱疮和类天疱疮疾病中的用途
US20250136706A1 (en) Methods For Prevention Of Graft Rejection In Xenotransplantation
JP2022529985A (ja) 抗ｐｓｍａ／ｃｄ３抗体で前立腺癌を治療する方法
EP4114863A1 (en) Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
JP2022529970A (ja) 抗ｐｓｍａ／ｃｄ３抗体で腎癌を治療する方法
US20220135695A1 (en) Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants
US20240368297A1 (en) Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
US20240132618A1 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
KR20240135663A (ko) 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
TWI870415B (zh) 使用抗cd38抗體之組合療法
KR20220058605A (ko) 고형 장기 이식 수여자의 장기 면역억제를 위한 칼시뉴린 억제제 불포함 ctla4-ig + 항-il6/il6r의 용도
JP2026513993A (ja) Ｃｄ３およびｃｄ２０に対する二重特異性抗体でリンパ腫を治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240816